{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:06Z","timestamp":1793383746072,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.mayocp.2026.01.008","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:36:29Z","timestamp":1774701389000},"page":"826-845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Polycythemia vera"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-1472","authenticated-orcid":false,"given":"Martin H.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2026.01.008_bib1","first-page":"384","article-title":"Sur une forme sp\u00e9ciale de cyanose s'accompanant d'hyperglobulie excessive et peristente. [On a special form of cyanosis accompanied by excessive and persistent erythrocytosis.]","volume":"9","author":"Vaquez","year":"1892","journal-title":"Bull et m\u00e9m Soc m\u00e9d d'hop de Paris, 3 s\u00e9"},{"key":"10.1016\/j.mayocp.2026.01.008_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00000441-190308000-00001","article-title":"Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity","volume":"126","author":"Osler","year":"1903","journal-title":"Am J Med Sci"},{"issue":"7037","key":"10.1016\/j.mayocp.2026.01.008_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.008_bib4","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemiavera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.008_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms\u2014trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-020-04287-w","article-title":"Is there a gender effect in polycythemia vera?","volume":"100","author":"Palandri","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.008_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.008_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41588-023-01638-x","article-title":"Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms","volume":"56","author":"Guo","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.mayocp.2026.01.008_bib9","doi-asserted-by":"crossref","first-page":"100710","DOI":"10.1016\/j.blre.2020.100710","article-title":"Germline genetic factors in the pathogenesis of myeloproliferative neoplasms","volume":"42","author":"Bellann\u00e9-Chantelot","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bjh.18165","article-title":"An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms","volume":"198","author":"Rabadan Moraes","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.008_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.clml.2019.06.001","article-title":"Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL Study","volume":"19","author":"Grunwald","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.008_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clml.2024.04.003","article-title":"Contemporary challenges in polycythemia vera management from the perspective of patients and physicians","volume":"24","author":"Kuykendall","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.008_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","article-title":"Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease","volume":"34","author":"Geyer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.008_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-2007-996121","article-title":"Erythromelalgia and vascular complications in polycythemia vera","volume":"23","author":"Michiels","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.008_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2141.2001.03161.x","article-title":"Pruritus in polycythaemia vera: prevalence, laboratory correlates and management","volume":"115","author":"Diehn","year":"2001","journal-title":"Br J Haematol"},{"issue":"33","key":"10.1016\/j.mayocp.2026.01.008_bib16","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.008_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.008_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.008_bib19","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2017.165795","article-title":"Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera","volume":"102","author":"Tang","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.008_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"7895","key":"10.1016\/j.mayocp.2026.01.008_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.mayocp.2026.01.008_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100280","article-title":"Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: a Mendelian randomization study","volume":"21","author":"Pedersen","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.008_bib23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood.2022016835","article-title":"Aging drives Tet2+\/- clonal hematopoiesis via IL-1 signaling","volume":"141","author":"Caiado","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.008_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mayocp.2026.01.008_bib25","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.008_bib26","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41408-025-01317-6","article-title":"Neutrophil-to-lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera","volume":"15","author":"Barbui","year":"2025","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.mayocp.2026.01.008_bib28","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.008_bib29","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.mayocp.2026.01.008_bib30","doi-asserted-by":"crossref","unstructured":"Barbui T., Vannucchi A.M., De Stefano V., et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175\u2013e184. Published correction appears in Lancet Haematol. 2021;8(3):e170. doi: 10.1016\/S2352-3026(21)00021-1.","DOI":"10.1016\/S2352-3026(20)30373-2"},{"issue":"19","key":"10.1016\/j.mayocp.2026.01.008_bib31","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 versus hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.008_bib32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2023-173127","article-title":"Final analysis of the Daliah trial: a randomized phase III trial of interferon-\u03b1 versus hydroxyurea in patients with MPN [abstract]","volume":"142","author":"Knudsen","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.008_bib33","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.mayocp.2026.01.008_bib34","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.008_bib35","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/ajh.27400","article-title":"Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia","volume":"99","author":"Guglielmelli","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.008_bib36","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.008_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000035","article-title":"Erythroferrone: an erythroid regulator of hepcidin and iron metabolism","volume":"2","author":"Coffey","year":"2018","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.26751","article-title":"The international consensusclassification of myeloid neoplasms and acute leukemias: myeloproliferativeneoplasms","volume":"98","author":"Thiele","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.008_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.008_bib41","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.008_bib42","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.008_bib43","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.008_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.008_bib45","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood-2024-193118","article-title":"Revised International Working Group risk model for survival in polycythemia vera [abstract]","volume":"144","author":"Tefferi","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.008_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.008_bib47","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","article-title":"Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification","volume":"38","author":"Pasquer","year":"2024","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.mayocp.2026.01.008_bib48","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2026.01.008_bib49","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2023020232","article-title":"Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL","volume":"143","author":"Gerds","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.008_bib50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.008_bib52","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.14382","article-title":"The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)","volume":"176","author":"Mesa","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.008_bib54","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.008_bib55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.008_bib56","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa2308809","article-title":"Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera","volume":"390","author":"Kremyanskaya","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2026.01.008_bib57","article-title":"Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)","volume":"43","author":"Kuykendall","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.008_bib58","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.008_bib59","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1111\/cts.13415","article-title":"Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: ex vivo and in vivo measurements and in silico simulation","volume":"15","author":"Petrucci","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.008_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.008_bib61","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.3390\/ijms21113900","article-title":"Drug-related cutaneous adverse events in Philadelphia chromosome-negative myeloproliferative neoplasms: a literature review","volume":"21","author":"Malato","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.008_bib62","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.008_bib63","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/ajh.27015","article-title":"SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers","volume":"98","author":"Porter","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mayocp.2026.01.008_bib64","unstructured":"A phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS 702843 administered to patients with phlebotomy dependent polycythemia vera (PD-PV). ClinicalTrials.gov identifier NCT05143957. Accessed June 30, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05143957, Updated January 16, 2026."},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.008_bib65","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2024-203255","article-title":"Phase 1 healthy volunteer study of DISC-3405, a recombinant humanized antibody targeting TMPRSS6 [abstract]","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.008_bib66","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/cpdd.1216","article-title":"Phase 1 clinical trial of PPMX-T003, a novel human monoclonal antibody specific for transferrin receptor 1, to evaluate its safety, pharmacokinetics, and pharmacodynamics","volume":"12","author":"Ogama","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.mayocp.2026.01.008_bib67","unstructured":"Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of givinostat versus Hydroxyurea in JAK2V617F-positive high-risk polycythemia vera patients: the GIV-IN PV Trial. ClinicalTrials.gov identifier NCT06093672. Accessed June 30, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06093672, Updated June 22, 2025."},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.008_bib68","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/13543784.2023.2267980","article-title":"Bomedemstat as an investigative treatment for myeloproliferative neoplasms","volume":"32","author":"Rienhoff","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.008_bib69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood-2023-179329","article-title":"Bomedemstat (IMG-7289), an LSD1 inhibitor, manages the signs and symptoms of essential thrombocythemia (ET) while reducing the burden of cells homozygous for driver mutations [abstract]","volume":"142","author":"Goethert","year":"2023","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626043296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626043296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:11:07Z","timestamp":1782133867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626043296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0025619626043296"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.01.008","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycythemia vera","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}